Plus Therapeutics Advances Pediatric Brain Tumor Treatment with New Clinical Study

Plus Therapeutics ((PSTV)) announced an update on their ongoing clinical study.

Plus Therapeutics is conducting a clinical study titled A Two-Part, Phase 1/2a Trial to Determine the Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL) Delivered Via Convection Enhanced Delivery (CED) in Supratentorial Recurrent, Refractory, or Progressive Pediatric Ependymoma and High-Grade Glioma (HGG). The study aims to determine the maximum tolerated dose of Rhenium-186 Nanoliposome in pediatric patients with specific brain tumors, assessing safety and potential efficacy.

The intervention being tested is Rhenium-186 Nanoliposome, a drug designed to deliver Rhenium-186 directly to tumor sites using convection enhanced delivery, maintaining localization and potentially improving treatment outcomes for difficult-to-treat pediatric brain tumors.

The study is interventional, non-randomized, and follows a sequential intervention model. It is unmasked and primarily focused on treatment. The study will progress through phases to establish the maximum tolerated dose and assess the treatment’s impact on tumor response and progression-free survival.

The study is set to begin in September 2025, with primary completion and estimated completion dates yet to be determined. The last update was submitted in July 2025, indicating the study is in the preparatory stages and not yet recruiting participants.

This update could influence Plus Therapeutics’ stock performance positively, as successful outcomes may lead to advancements in treating pediatric brain tumors, a significant unmet medical need. Investors might view this as a promising development, especially in comparison to competitors focusing on similar therapeutic areas.

The study is ongoing, with further details available on the ClinicalTrials portal.